Research and Clinical Trials

TACE and MWA Combination Therapy for Early Stage HCC
Brief Description  
This study will compare the results of transarterial chemoembolization (TACE) and microwave ablation (MWA) combination therapy with MWA monotherapy for the treatment of early (stages 0 and A) hepatocellular carcinoma (HCC). The primary aim is to compare 2 year intrahepatic disease-free survival. Secondary aims are: 1) to determine the clinical feasibility of TACE + MWA in HCC patients with a small tumor burden and 2) to determine the effect of TACE on radiographic tumor characteristics.
Who may be Eligible  
Male or female patients aged 18 to 75 years with a primary diagnosis of hepatocellular carcinoma.
Start Date  
IRB Number  
Principal Investigator  
Vrochides, Dionisios
Contact Name  

For More Information, Contact  Dionisios  , Vrochides
Phone:  (704) 446-4855  Fax:  (704) 446-4872  
Address:1025 Morehead Medical Drive, Suite 600 Charlotte, NC 28204